Latest news with #AmdocsLimited
Yahoo
13-05-2025
- Business
- Yahoo
Amdocs (NASDAQ:DOX) Has Announced A Dividend Of $0.527
Amdocs Limited (NASDAQ:DOX) will pay a dividend of $0.527 on the 25th of July. This makes the dividend yield about the same as the industry average at 2.3%. We check all companies for important risks. See what we found for Amdocs in our free report. While it is always good to see a solid dividend yield, we should also consider whether the payment is feasible. The last dividend was quite easily covered by Amdocs' earnings. This indicates that quite a large proportion of earnings is being invested back into the business. The next year is set to see EPS grow by 7.5%. Assuming the dividend continues along recent trends, we think the payout ratio could be 43% by next year, which is in a pretty sustainable range. View our latest analysis for Amdocs The company has a sustained record of paying dividends with very little fluctuation. The annual payment during the last 10 years was $0.62 in 2015, and the most recent fiscal year payment was $2.11. This implies that the company grew its distributions at a yearly rate of about 13% over that duration. Rapidly growing dividends for a long time is a very valuable feature for an income stock. Investors who have held shares in the company for the past few years will be happy with the dividend income they have received. Amdocs has seen EPS rising for the last five years, at 5.6% per annum. Earnings are on the uptrend, and it is only paying a small portion of those earnings to shareholders. In summary, it is always positive to see the dividend being increased, and we are particularly pleased with its overall sustainability. Earnings are easily covering distributions, and the company is generating plenty of cash. All of these factors considered, we think this has solid potential as a dividend stock. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. However, there are other things to consider for investors when analysing stock performance. Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 5 analysts we track are forecasting for Amdocs for free with public analyst estimates for the company. Is Amdocs not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
08-04-2025
- Business
- Yahoo
Amdocs' (NASDAQ:DOX) earnings growth rate lags the 9.1% CAGR delivered to shareholders
Amdocs Limited (NASDAQ:DOX) shareholders might be concerned after seeing the share price drop 10% in the last week. But the silver lining is the stock is up over five years. In that time, it is up 40%, which isn't bad, but is below the market return of 94%. While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. During five years of share price growth, Amdocs achieved compound earnings per share (EPS) growth of 4.1% per year. This EPS growth is slower than the share price growth of 7% per year, over the same period. So it's fair to assume the market has a higher opinion of the business than it did five years ago. That's not necessarily surprising considering the five-year track record of earnings growth. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It might be well worthwhile taking a look at our free report on Amdocs' earnings, revenue and cash flow . It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Amdocs, it has a TSR of 55% for the last 5 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! We regret to report that Amdocs shareholders are down 3.8% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 2.4%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 9%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Is Amdocs cheap compared to other companies? These 3 valuation measures might help you decide. We will like Amdocs better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
10-02-2025
- Business
- Yahoo
Amdocs' (NASDAQ:DOX) Shareholders Will Receive A Bigger Dividend Than Last Year
The board of Amdocs Limited (NASDAQ:DOX) has announced that the dividend on 25th of April will be increased to $0.527, which will be 10% higher than last year's payment of $0.479 which covered the same period. This takes the annual payment to 2.2% of the current stock price, which is about average for the industry. See our latest analysis for Amdocs While it is always good to see a solid dividend yield, we should also consider whether the payment is feasible. Based on the last payment, Amdocs was quite comfortably earning enough to cover the dividend. This means that a large portion of its earnings are being retained to grow the business. The next year is set to see EPS grow by 39.0%. Assuming the dividend continues along recent trends, we think the payout ratio could be 36% by next year, which is in a pretty sustainable range. Even over a long history of paying dividends, the company's distributions have been remarkably stable. Since 2015, the annual payment back then was $0.62, compared to the most recent full-year payment of $1.92. This implies that the company grew its distributions at a yearly rate of about 12% over that duration. So, dividends have been growing pretty quickly, and even more impressively, they haven't experienced any notable falls during this period. Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Earnings per share has been crawling upwards at 4.6% per year. Amdocs is struggling to find viable investments, so it is returning more to shareholders. While this isn't necessarily a negative, it definitely signals that dividend growth could be constrained in the future unless earnings start to pick up again. In summary, it is always positive to see the dividend being increased, and we are particularly pleased with its overall sustainability. Distributions are quite easily covered by earnings, which are also being converted to cash flows. Taking this all into consideration, this looks like it could be a good dividend opportunity. Investors generally tend to favour companies with a consistent, stable dividend policy as opposed to those operating an irregular one. Meanwhile, despite the importance of dividend payments, they are not the only factors our readers should know when assessing a company. Companies that are growing earnings tend to be the best dividend stocks over the long term. See what the 6 analysts we track are forecasting for Amdocs for free with public analyst estimates for the company. Is Amdocs not quite the opportunity you were looking for? Why not check out our selection of top dividend stocks. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Associated Press
04-02-2025
- Business
- Associated Press
Amdocs Limited Reports First Quarter Fiscal 2025 Results
Revenue of $1.11 Billion, down 10.9% YoY as Reported and up 1.7% YoY in Pro Forma(1) Constant Currency(2) Delivers Substantial Profitability Improvement, Reflecting Phase Out of Certain Non-Core, Low Margin Business Activities & Operational Efficiencies 12-Month Backlog of $4.14 Billion, Accelerating by $80 Million QoQ and up 2.7% YoY on a Pro Forma(1) Basis Expects Fiscal 2025 Revenue Outlook of (11.6)%-(8.5)% YoY as Reported Reiterates Fiscal 2025 Revenue Growth Outlook of 1%-4.5% YoY in Pro Forma(1) Constant Currency(2) Reiterates Fiscal 2025 Target for Double-Digit Total Shareholder Returns(3) First Quarter Fiscal 2025 Highlights (All comparisons are against the prior year) (1) For comparison purposes, pro forma adjusts first quarter fiscal year 2024 revenue by approximately $150 million and fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook (2) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period (3) Expected total shareholder return assumes midpoint of fiscal year 2025 non-GAAP EPS growth outlook, plus dividend yield (4) Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding) JERSEY CITY, NJ / ACCESS Newswire / February 4, 2025 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended December 31, 2024. 'Fiscal 2025 is off to a solid start. First quarter revenue of $1.11 billion was slightly above the midpoint of guidance adjusting for currency, and 12-month backlog accelerated by $80 million sequentially. Among several key wins this quarter Amdocs is leading a billing systems consolidation for a large Tier 1 operator in North America. We also saw the continuation of strong sales momentum in cloud where we signed a new cloud operations services agreement with a large Western European provider. From an execution standpoint, we successfully delivered many project deployments for our customers, including the launch of new charging platform for a European operator and M1 in Singapore. Additionally, we remain laser-focused on delivering world-class innovation in cloud, digital and Gen AI-based solutions that service providers need to grow revenue, improve efficiency and deliver exceptional customer experiences,' said Shuky Sheffer, president and chief executive officer of Amdocs Management Limited. 'Profitability rose significantly in Q1, driven by the previously announced phase-out of low-margin activities, and our focus on operational excellence, automation, and AI to drive ongoing efficiency gains. Further supporting our high level of business visibility, managed services accounted for roughly 66% of total revenue, a material improvement from a year ago. Additionally, we expanded the scope of existing managed services engagements with several customers, maintaining our impressive renewal rate which has trended close to 100% over time,' said Tamar Rapaport-Dagim, chief financial officer & chief operating officer of Amdocs Management Limited. Sheffer concluded, 'As a market leader, we are proud of Amdocs' innovative, Gen AI-based solutions and our execution and mission critical operations expertise. We also have a pivotal role in supporting our customers growth, efficiency and industry consolidation strategies. Across our large addressable market, we see a rich and encouraging sales pipeline which we are working hard to monetize while navigating the continuously challenging demand environment. As to our fiscal 2025 outlook, we are reiterating our guidance for revenue growth of between 1% to 4.5% in pro forma(1) constant currency(2), as well as another year of double-digit growth in cloud. Moreover, we are on-track to deliver double-digit expected total shareholder returns(3) for the fifth consecutive year, underpinned by our ongoing margin expansion initiatives and robust earnings to cash conversion.' (All comparisons are against the prior year period) Revenue for the first fiscal quarter of 2025 was slightly above the midpoint of Amdocs' guidance, adjusting for negative impact from foreign currency movements of approximately $6 million relative to our guidance assumptions Revenue for the first fiscal quarter includes a negative impact from foreign currency movements of approximately $4 million relative to the fourth quarter of fiscal 2024 Net Income and Earnings Per Share In thousands, except per share data Three months ended December 31, 2024 2023 GAAP Measures Net Income $151,852 $148,722 Net Income attributable to Amdocs Limited $151,133 $147,965 Diluted earnings per share $1.33 $1.26 Non-GAAP Measures Non-GAAP Net Income $188,877 $183,833 Non-GAAP Net Income attributable to Amdocs Limited $188,158 $183,076 Non-GAAP Diluted earnings per share $1.66 $1.56 Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below. Capital Allocation M&A Activity: On December 31, 2024, Amdocs completed the acquisition of Profinit, a data science and engineering company, for a net consideration of approximately $34 million with additional consideration to be paid later based on the achievement of certain performance objectives, as well as two smaller acquisitions Quarterly Cash Dividend Program: On February 4, 2025, the Board approved the Company's next quarterly cash dividend payment at the new increased rate of $0.527 per share, as approved at the January 2025 annual general meeting of shareholders and set March 31, 2025 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on April 25, 2025 Share Repurchase Activity: Repurchased $144 million of ordinary shares during the first quarter of fiscal 2025 Twelve-month Backlog Twelve-month backlog was $4.14 billion at the end of the first quarter of fiscal 2025. On a pro forma(1) basis, adjusting the comparable period for the phase out of certain business activities, twelve-month backlog was up approximately 2.7% as compared to last year's first fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities. Second Quarter Fiscal 2025 Outlook Second quarter revenue guidance assumes a negative $3 million sequential impact from foreign currency fluctuations as compared to foreign currency rates prevailing at the end of the first quarter of fiscal 2025 Second quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.20-$0.22 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.12 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects GAAP diluted EPS guidance does not include the impact of future restructuring charges Full Year Fiscal 2025 Outlook FY 2025 - Year-over -Year growth Current guidance Previous guidance Revenue Growth, as reported (11.6)%-(8.4)% (10.9)%-(7.7)% Revenue Growth, Pro-forma (1) constant currency (2) 1%-4.5% 1%-4.5% GAAP Diluted earnings per share 27.0%-34.0% 25.0%-33.0% Non-GAAP Diluted earnings per share 6.5%-10.5% 6.5%-10.5% FY 2025, in millions Current guidance Previous guidance Free Cash Flow (4) $ 710-$730 $ 710-$730 Revenue growth on a pro forma(1), constant currency(2) basis adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of several low-margin, non-core business activities, including certain low-margin software and hardware partner activities, Vubiquity's transactional video on demand business and non-core subscription services; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook Full year fiscal 2025 revenue guidance incorporates an expected negative impact from foreign currency fluctuations of approximately 0.6% year-over-year, as compared with a positive impact of approximately 0.2% year-over-year previously, and includes some inorganic contribution Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.84-$0.90 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.48 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects The impact of the acquisitions on Amdocs' non-GAAP diluted earnings per share is expected to be immaterial in the full fiscal year 2025 GAAP diluted EPS guidance does not include the impact of future restructuring charges Non-GAAP operating margin is anticipated to be within a range of 21.1% to 21.7% for the full year fiscal 2025 Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value Non-GAAP effective tax rate is anticipated to be within a range of 15% to 17% for the full year fiscal 2025 Free cash flow(4) is comprised of cash flow from operations, less net capital expenditures, and excludes payments related to restructuring charges The forward-looking statements regarding our second fiscal quarter 2025 and full year fiscal 2025 guidance take into consideration the Company's current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. Conference Call and Earnings Webcast Presentation Details Amdocs will host a conference call and earnings webcast presentation on February 4, 2025 at 5:00 p.m. Eastern Time to discuss the Company's first quarter of fiscal 2025 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at Presentation slides will be available shortly before the webcast. Non-GAAP Financial Measures This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items: Free cash flow equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow(4), revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business. For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items. Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below. Supporting Resources About Amdocs Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers' innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our employees around the globe are here to accelerate service providers' migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $5.00 billion in fiscal 2024. For more information, visit Amdocs at This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers. Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024 filed on December 17, 2024. Contact: Head of Investor Relations Amdocs 314-212-8328 AMDOCS LIMITED Consolidated Statements of Income (In thousands, except per share data) Three months ended December 31, 2024 2023 Revenue $ 1,110,055 $ 1,245,199 Operating expenses: Cost of revenue 682,259 812,744 Research and development 84,333 89,207 Selling, general and administrative 122,087 142,504 Amortization of purchased intangible assets and other 15,759 16,410 Restructuring charges 6,783 - 911,221 1,060,865 Operating income 198,834 184,334 Interest and other expense, net (6,409 ) (9,778 ) Income before income taxes 192,425 174,556 Income tax expense 40,573 25,834 Net income $ 151,852 $ 148,722 Net income attributable to noncontrolling interests 719 757 Net income attributable to Amdocs Limited $ 151,133 $ 147,965 Basic earnings per share attributable to Amdocs Limited $ 1.34 $ 1.27 Diluted earnings per share attributable to Amdocs Limited $ 1.33 $ 1.26 Cash dividends declared per ordinary share $ 0.479 $ 0.435 Basic weighted average number of shares outstanding 112,745 116,841 Diluted weighted average number of shares outstanding 113,439 117,536 AMDOCS LIMITED Selected Financial Metrics (In thousands, except per share data) Free Cash Flows (In thousands) Three months ended December 31, 2024 2023 Net Cash Provided by Operating Activities $ 105,555 $ 182,387 Purchase of property and equipment, net (a) (27,355 ) (43,743 ) Free Cash Flow $ 78,200 $ 138,644 (a) The amounts under 'Purchase of property and equipment, net', include immaterial proceeds from sale of property and equipment for the three months ended December 31, 2024 and 2023, respectively. AMDOCS LIMITED Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP (In thousands) Three Months Ended December 31, 2023 GAAP Amortization of purchased intangible assets and other Equity based compensation expense Changes in certain acquisitions related liabilities measured at fair value Other Tax effect Non-GAAP Operating expenses: Cost of revenue $ 812,744 $ - $ (13,527 ) $ 1,583 $ - $ - $ 800,800 Research and development 89,207 (1,867 ) 87,340 Selling, general and administrative 142,504 (10,686 ) 131,818 Amortization of purchased intangible assets and other 16,410 (16,410 ) - Total operating expenses 1,060,865 (16,410 ) (26,080 ) 1,583 - - 1,019,958 Operating income 184,334 16,410 26,080 (1,583 ) - - 225,241 Interest and other expense, net (9,778 ) 1,534 (8,244 ) Income tax expense 25,834 7,330 33,164 Net income 148,722 16,410 26,080 (1,583 ) 1,534 (7,330 ) 183,833 Net income attributable to noncontrolling interests 757 757 Net income attributable to Amdocs Limited $ 147,965 $ 16,410 $ 26,080 $ (1,583 ) $ 1,534 $ (7,330 ) $ 183,076 AMDOCS LIMITED Condensed Consolidated Balance Sheets (In thousands) As of December 31, 2024 September 30, 2024 ASSETS Current assets: Cash and cash equivalents $ 213,833 $ 346,085 Short-term interest-bearing investments 135,175 168,242 Accounts receivable, net, including unbilled 990,859 1,028,357 Prepaid expenses and other current assets 266,861 228,498 Total current assets 1,606,728 1,771,182 Property and equipment, net 734,400 755,601 Lease assets 155,485 149,254 Goodwill and other intangible assets, net 3,066,911 3,005,637 Other noncurrent assets 730,217 704,468 Total assets $ 6,293,741 $ 6,386,142 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities Accounts payable, accruals and other $ 1,230,093 $ 1,315,679 Lease liabilities 38,625 39,983 Deferred revenue 116,114 115,247 Total current liabilities 1,384,832 1,470,909 Lease liabilities 108,722 103,462 Long-term debt, net of unamortized debt issuance costs 646,444 646,291 Other noncurrent liabilities 647,883 666,303 Total Amdocs Limited Shareholders' equity 3,464,263 3,456,976 Noncontrolling interests 41,597 42,201 Total equity 3,505,860 3,499,177 Total liabilities and equity $ 6,293,741 $ 6,386,142 AMDOCS LIMITED Consolidated Statements of Cash Flows (In thousands) Three months ended December 31, 2024 2023 Cash Flow from Operating Activities: Net income $ 151,852 $ 148,722 Reconciliation of net income to net cash provided by operating activities: Depreciation, amortization and impairment 46,415 45,861 Amortization of debt issuance cost 151 149 Equity-based compensation expense 26,520 26,080 Deferred income taxes 1,651 (6,683 ) Loss from short-term interest-bearing investments 662 548 Net changes in operating assets and liabilities, net of amounts acquired: Accounts receivable, net 2,417 (66,657 ) Prepaid expenses and other current assets (14,787 ) 4,452 Other noncurrent assets (7,925 ) (10,538 ) Lease assets and liabilities, net (2,329 ) (5,340 ) Accounts payable, accrued expenses and accrued personnel (50,837 ) 95,787 Deferred revenue 867 (25,930 ) Income taxes payable, net (5,129 ) (18,066 ) Other noncurrent liabilities (43,973 ) (5,998 ) Net cash provided by operating activities 105,555 182,387 Cash Flow from Investing Activities: Purchase of property and equipment, net (a) (27,355 ) (43,743 ) Proceeds from sale of short-term interest-bearing investments 33,362 8,534 Net cash paid for business acquisitions (57,083 ) (77,329 ) Net Cash from equity investments and other 16,347 928 Net cash used in investing activities (34,729 ) (111,610 ) Cash Flow from Financing Activities: Repurchase of shares (144,483 ) (158,525 ) Proceeds from employee stock option exercises 4,408 4,428 Payments of dividends (54,081 ) (51,053 ) Distribution to noncontrolling interests (1,323 ) (1,322 ) Payment of contingent consideration and deferred payment of business acquisitions (7,599 ) (1,500 ) Net cash used in financing activities (203,078 ) (207,972 ) Net decrease in cash and cash equivalents (132,252 ) (137,195 ) Cash and cash equivalents at beginning of period 346,085 520,080 Cash and cash equivalents at end of period $ 213,833 $ 382,885 AMDOCS LIMITED Supplementary Information (In millions) Three months ended December 31, September 30, June 30, March 31, December 31, 2024 2024 2024 2024 2023 North America $ 737.4 $ 835.8 $ 828.8 $ 823.2 $ 838.1 Europe 155.2 184.1 175.9 184.8 181.4 Rest of the World 217.4 244.0 245.3 237.8 225.7 Total Revenue $ 1,110.1 $ 1,263.9 $ 1,250.1 $ 1,245.8 $ 1,245.2 Three months ended December 31, September 30, June 30, March 31, December 31, 2024 2024 2024 2024 2023 Managed Services Revenue $ 728.9 $ 721.4 $ 740.8 $ 720.3 $ 722.5 as of December 31, September 30, June 30, March 31, December 31, 2024 2024 (*) 2024 2024 2023 12-Month Backlog $ 4,140 $ 4,060 $ 4,250 $ 4,230 $ 4,210 (*) Reflects the phase out of certain business activities from the fourth fiscal quarter of 2024 onwards. SOURCE: Amdocs - IR
